Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PDLIM2 repression by ROS in alveolar macrophages promotes lung tumorigenesis
Liwen Li, … , Gutian Xiao, Zhaoxia Qu
Liwen Li, … , Gutian Xiao, Zhaoxia Qu
Published February 4, 2021
Citation Information: JCI Insight. 2021;6(5):e144394. https://doi.org/10.1172/jci.insight.144394.
View: Text | PDF
Research Article Oncology

PDLIM2 repression by ROS in alveolar macrophages promotes lung tumorigenesis

  • Text
  • PDF
Abstract

One of the most fundamental and challenging questions in the field of cancer is how immunity is transformed from tumor immunosurveillance to tumor-promoting inflammation. Here, we identified the tumor suppressor PDZ-LIM domain–containing protein 2 (PDLIM2) as a checkpoint of alveolar macrophages (AMs) important for lung tumor suppression. During lung tumorigenesis, PDLIM2 expression in AMs is downregulated by ROS-activated transcription repressor BTB and CNC homology 1 (BACH1). PDLIM2 downregulation leads to constitutive activation of the transcription factor STAT3, driving AM protumorigenic polarization/activation and differentiation from monocytes attracted from the circulation to suppress cytotoxic T lymphocytes and promote lung cancer. PDLIM2 downregulation also decreases AM phagocytosis. These findings establish ROS/BACH1/PDLIM2/STAT3 as a signaling pathway driving AMs for lung tumor promotion.

Authors

Liwen Li, Fan Sun, Lei Han, Xujie Liu, Yadong Xiao, Alyssa D. Gregory, Steven D. Shapiro, Gutian Xiao, Zhaoxia Qu

×

Figure 1

Critical role of cell-intrinsic PDLIM2 in AM phagocytosis and restricting AM protumorigenic activation and suppression of CTLs during lung tumorigenesis.

Options: View larger image (or click on image) Download as PowerPoint
Critical role of cell-intrinsic PDLIM2 in AM phagocytosis and restrictin...
(A and B) IHC and IF staining showing PDLIM2-selective deletion in pulmonary myeloid cells of PDLIM2mKO mice. Arrows indicate myeloid cells. Scale bar: 20 μm. (C) Experimental schedule of lung tumor induction by urethane. (D) Tumor examination and H&E staining showing increased lung tumor numbers and tumor burden in urethane-treated PDLIM2mKO mice (n = 8). Scale bar: 2.5 mm. (E) FACS analysis showing defective phagocytic ability of AMs from urethane-treated PDLIM2mKO mice (n = 6). (F) qPCR showing increased expression of Vegfa and Mrc1 in the AMs of urethane-treated PDLIM2mKO mice (n = 7); 18S rRNA was used as internal control. (G) Immunofluorescent (IF) analysis showing increased Arginase 1 in the AMs of urethane-treated PDLIM2mKO mice (n = 3). Scale bar: 20 μm. (H) Ex vivo coculture assays showing increased repression of CD8+ T cells by PDLIM2-/- AMs (n = 4). The activity of CD8+ T cells was analyzed 2 days after coculture with AMs. (I) FACS analysis showing decreased activation of lung CD8+ T cells in urethane-treated PDLIM2mKO mice (n = 8). Student’s t test (2 tailed, unpaired) (D–G, and I) and ordinary 1-way ANOVA (H) were performed, and data represent mean ± SEM. *P < 0.05; **P < 0.01; ns, not statistically significant; GrB, Granzyme B.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts